Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AYTU BIOPHARMA, INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
3.22
3.66
7.32
27.6
65.6
96.7
107
65.2
66.4
57.6
Cost of revenue
1.42
2.05
2.2
8.28
36.4
44.4
40.8
16.1
20.6
20.8
Gross profit
1.8
1.61
5.12
19.4
29.2
52.3
66.6
49.1
45.8
36.8
Research and development
0.96
0.17
0.59
1.72
5.62
12.7
4.1
2.77
1.33
0
Selling, general and administrative
17.4
17.7
18.9
34.8
Selling and marketing
11.4
30.3
38.7
41.4
22.1
20.9
23.4
General and administrative
19.7
25.5
31.2
28.6
20
17.4
19.3
Operating expenses
23.3
23.4
24.2
40.5
88.1
162
83.7
50.6
53.7
45.1
Operating income
-20.1
-19.7
-16.8
-21.1
-58.9
-110
-17.1
-1.59
-7.83
-8.32
Interest expense
2.53
0.75
0.54
2.61
0.9
4.96
5.06
3.7
1.9
Other non-operating income
-2.38
9.51
-10.3
7.51
0.84
1.02
0.01
0.87
-0.51
0.71
Pre-tax income
-13.6
-58
-109
-17.1
-10.4
-13.7
-14.2
Income tax
0
0
0
0
0.26
-0.11
0
2.14
0.44
0.02
Income from continuing operations
-12.5
-14.2
-14.3
Net income
-22.5
-10.2
-27.1
-13.6
-58.3
-109
-17.1
-15.8
-13.6
-14.3
EBITDA
-15.8
-17.1
-14.1
-15.4
-49.7
-99.8
-8.25
6.68
-2.45
-4.39
EPS, basic
-9,564.00
-3,032.00
-689.10
-59.41
-68.68
-74.01
-5.11
-2.86
-2.16
-1.16
EPS, diluted
-9,564.00
-3,032.00
-689.10
-59.41
-68.68
-74.01
-5.11
-2.86
-2.16
-1.16
Shares, basic (weighted)
0
0
0.04
0.23
0.85
1.47
3.34
5.54
6.28
12.3
Shares, diluted (weighted)
0
0
0.04
0.23
0.85
1.47
3.34
5.54
6.28
12.3
Balance sheet
FY2017
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
0.8
7.01
11
48.1
49.6
19.4
23
20
31
26.3
Short-term investments
0
Receivables
0.53
0.58
1.74
5.63
28.2
21.7
28.9
23.5
31.2
22.8
Inventory
1.31
1.34
1.44
10
16.3
10.8
12
12.1
11.4
6.86
Other current assets
0.31
0.44
0
5.74
1.04
0.63
71.1
61.9
5.64
5.81
Total current assets
3.03
9.47
15.4
75.4
105
59.9
72.8
61.9
79.2
61.8
Property, plant and equipment
0.65
0.22
0.2
0.26
5.14
3.03
1.82
0.69
0.53
0.39
Lease right-of-use assets
0
0.63
3.56
3.27
2.05
0.83
1.06
0.86
Goodwill
0.24
0
28.1
65.8
0
0
Intangible assets
0.27
0.25
48.9
48.9
85.5
70.6
59
52.5
42.2
41.4
Other non-current assets
9.23
11.1
18.9
0.03
0.47
0.77
2.55
2.19
1.2
0.6
Total assets
15
21.1
34.7
153
266
138
136
118
124
105
Accounts payable
2.22
2.12
2.13
11.6
19.3
13.5
10.3
10.6
11.3
Accrued liabilities
0.78
0.19
1.31
8.83
57.2
44.2
46.8
38.1
38.2
35.2
Deferred revenue
0
0
0.34
0.2
0.4
Short-term debt
0
0.98
16.7
0.1
0.09
1.86
1.86
1.86
Total current liabilities
3.61
3.39
5.37
28.8
109
64.4
69
62.2
63.1
54.7
Long-term debt
0
0.18
14.3
14.7
10.9
10.9
9.1
Lease liabilities
0
0.73
2.62
2.09
0.83
0.58
0.99
0.85
Other non-current liabilities
0
0.01
18.5
12.8
6.98
4.53
4.92
4.77
Total liabilities
11
7.64
27.6
58.3
128
93.3
97.1
90.4
105
69.7
Total debt
0
0
0.98
16.8
15
15
12.7
12.8
11
Paid-in capital
73.1
92.7
113
215
316
331
343
348
353
383
Retained earnings
-69.1
-79.3
-106
-120
-178
-287
-304
-320
-334
-348
Shareholders' equity
4
13.4
7.09
95
138
44.3
39.4
27.7
19
35.3
Total equity
4
13.4
7.09
95
138
44.3
39.4
27.7
19
35.3
Total liabilities and equity
15
21.1
34.7
153
266
138
136
118
124
105
Shares outstanding
0
0.01
0.09
0.64
1.39
1.93
5.52
5.97
8.98
10.7
Cash flow statement
FY2017
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-22.5
-10.2
-27.1
-13.6
-58.3
-109
-17.1
-15.8
-13.6
-14.3
Depreciation and amortization
4.36
2.59
2.73
5.71
9.2
10.1
8.82
8.27
5.38
3.93
Stock-based compensation
2.5
0.6
1.02
1.08
3.57
5.25
6.05
2.37
0.58
0.69
Deferred income tax
0.24
-0.12
-0.13
0
Change in receivables
-0.36
-0.05
-1.16
-3.56
1.54
6.53
-7.15
5.2
-7.63
8.38
Change in inventory
0.2
-0.03
-0.1
-8.22
2.79
1.3
-3.61
-4.82
0.38
2.39
Change in payables
0.49
-0.11
0.13
-1.38
-3.25
-7.68
2.38
-2.08
0.29
-2.32
Cash from operations
-13.8
-15.9
-13.8
-28.4
-26
-28.8
-5.13
-1.39
-1.94
3.28
Capital expenditures
-0.11
-0.07
-0.06
0
-2.34
0
-0.33
-0.23
-0.03
Acquisitions
-0.3
-5.85
-15.5
0
Purchases of investments
-0.09
Cash from investing
-3.53
-0.48
-1.06
-5.66
-2.78
-3.25
-0.12
-0.33
-2.56
-0.03
Debt issued
0
0
0.64
13
1.86
0
Debt repaid
-0.1
-15.7
-1.86
-1.86
Stock issued
0.74
65.7
45.1
11.7
15.6
Cash from financing
10.2
22.7
19.1
71.1
30.3
1.53
8.87
-1.26
15.4
-7.9
Net change in cash
-7.18
6.23
4.18
37
1.57
-30.5
3.63
-2.98
10.9
-4.64
Free cash flow
-13.9
-16
-13.9
-28.4
-28.3
-28.8
-1.72
-2.17
3.25
Interest paid
0
1.04
1.25
3.15
3.81
4.04
2.82
1.79
Income taxes paid
0
1.61
1.42
0.21
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $2.28 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
64.0%
Gross profit / revenue.
Operating margin
-14.4%
Operating income / revenue.
EBITDA margin
-7.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-24.7%
Pre-tax income / revenue.
Net margin
-24.8%
Net income / revenue.
FCF margin
5.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
5.7%
Cash from operations / revenue.
Return on equity (ROE)
-52.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-12.4%
Net income / average total assets.
Return on invested capital (ROIC)
-63.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
0.0%
Research and development expense / revenue.
Stock-based pay / revenue
1.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
6.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-13.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-18.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-2.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-19.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-17.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
4.7%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
86.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-3.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-23.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-15.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-8.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-16.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
96.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
54.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
70.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.13x
Current assets / current liabilities.
Quick ratio
0.90x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.48x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.31x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
10.4%
Total debt / total assets.
Liabilities / assets
66.4%
Total liabilities / total assets.
Net debt
-$15.4M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
0.9%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.16
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$1.16
Net income per basic share, as reported (split-adjusted).
Revenue per share
$4.67
Revenue / diluted weighted shares.
FCF per share
$0.26
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.27
Cash from operations / diluted weighted shares.
Book value per share
$3.29
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.43x
Market cap / revenue.
P/B
0.69x
Market cap / shareholders' equity. Only when equity is positive.
P/FCF
7.53x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
7.46x
Market cap / cash from operations, when positive.
EV/Sales
0.16x
Enterprise value / revenue.
EV/FCF
2.80x
Enterprise value / free cash flow, when both are positive.
FCF yield
13.3%
Free cash flow / market cap.
Earnings yield
-58.2%
Net income / market cap (the inverse of P/E).
What was AYTU BIOPHARMA, INC's revenue in fiscal 2026?
AYTU BIOPHARMA, INC reported revenue of $57.6M for fiscal 2026, 13.3% lower than the year before.
Was AYTU BIOPHARMA, INC profitable in fiscal 2026?
No. It reported a net loss of $14.3M.
How much free cash flow did AYTU BIOPHARMA, INC generate in fiscal 2026?
Cash from operations of $3.3M minus capital expenditures of $29.0K left free cash flow of $3.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.